The evolving genomic landscape of urothelial carcinoma

Alexander P. Glaser, Damiano Fantini, Ali Shilatifard, Edward M. Schaeffer, Joshua J. Meeks*

*Corresponding author for this work

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Survival of patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma) is limited by our current approaches to staging, surgery, and chemotherapy. Large-scale, next-generation sequencing collaborations, such as The Cancer Genome Atlas, have already identified drivers and vulnerabilities of urothelial carcinoma. This disease has a high degree of mutational heterogeneity and a high frequency of somatic mutations compared with other solid tumours, potentially resulting in an increased neoantigen burden. Mutational heterogeneity is mediated by multiple factors including the apolipoprotein B mRNA editing enzyme catalytic polypeptide family of enzymes, smoking exposure, viral integrations, and intragene and intergene fusion proteins. The mutational landscape of urothelial carcinoma, including specific mutations in pathways and driver genes, such as FGFR3, ERBB2, PIK3CA, TP53, and STAG2, affects tumour aggressiveness and response to therapy. The next generation of therapies for urothelial carcinoma will be based on patient-specific targetable mutations found in individual tumours. This personalized-medicine approach to urothelial carcinoma has already resulted in unique clinical trial design and has the potential to improve patient outcomes and survival.

Original languageEnglish (US)
Pages (from-to)215-229
Number of pages15
JournalNature Reviews Urology
Volume14
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Carcinoma
Neoplasms
Virus Integration
Precision Medicine
Mutation
Survival
Atlases
Mutation Rate
Urinary Bladder Neoplasms
Smoking
Clinical Trials
Genome
Drug Therapy
Enzymes
Therapeutics
Genes
Proteins

ASJC Scopus subject areas

  • Urology

Cite this

@article{aa651c4aeb12462b9efce6cbfa37e66e,
title = "The evolving genomic landscape of urothelial carcinoma",
abstract = "Survival of patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma) is limited by our current approaches to staging, surgery, and chemotherapy. Large-scale, next-generation sequencing collaborations, such as The Cancer Genome Atlas, have already identified drivers and vulnerabilities of urothelial carcinoma. This disease has a high degree of mutational heterogeneity and a high frequency of somatic mutations compared with other solid tumours, potentially resulting in an increased neoantigen burden. Mutational heterogeneity is mediated by multiple factors including the apolipoprotein B mRNA editing enzyme catalytic polypeptide family of enzymes, smoking exposure, viral integrations, and intragene and intergene fusion proteins. The mutational landscape of urothelial carcinoma, including specific mutations in pathways and driver genes, such as FGFR3, ERBB2, PIK3CA, TP53, and STAG2, affects tumour aggressiveness and response to therapy. The next generation of therapies for urothelial carcinoma will be based on patient-specific targetable mutations found in individual tumours. This personalized-medicine approach to urothelial carcinoma has already resulted in unique clinical trial design and has the potential to improve patient outcomes and survival.",
author = "Glaser, {Alexander P.} and Damiano Fantini and Ali Shilatifard and Schaeffer, {Edward M.} and Meeks, {Joshua J.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1038/nrurol.2017.11",
language = "English (US)",
volume = "14",
pages = "215--229",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "4",

}

The evolving genomic landscape of urothelial carcinoma. / Glaser, Alexander P.; Fantini, Damiano; Shilatifard, Ali; Schaeffer, Edward M.; Meeks, Joshua J.

In: Nature Reviews Urology, Vol. 14, No. 4, 01.04.2017, p. 215-229.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The evolving genomic landscape of urothelial carcinoma

AU - Glaser, Alexander P.

AU - Fantini, Damiano

AU - Shilatifard, Ali

AU - Schaeffer, Edward M.

AU - Meeks, Joshua J.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Survival of patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma) is limited by our current approaches to staging, surgery, and chemotherapy. Large-scale, next-generation sequencing collaborations, such as The Cancer Genome Atlas, have already identified drivers and vulnerabilities of urothelial carcinoma. This disease has a high degree of mutational heterogeneity and a high frequency of somatic mutations compared with other solid tumours, potentially resulting in an increased neoantigen burden. Mutational heterogeneity is mediated by multiple factors including the apolipoprotein B mRNA editing enzyme catalytic polypeptide family of enzymes, smoking exposure, viral integrations, and intragene and intergene fusion proteins. The mutational landscape of urothelial carcinoma, including specific mutations in pathways and driver genes, such as FGFR3, ERBB2, PIK3CA, TP53, and STAG2, affects tumour aggressiveness and response to therapy. The next generation of therapies for urothelial carcinoma will be based on patient-specific targetable mutations found in individual tumours. This personalized-medicine approach to urothelial carcinoma has already resulted in unique clinical trial design and has the potential to improve patient outcomes and survival.

AB - Survival of patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma) is limited by our current approaches to staging, surgery, and chemotherapy. Large-scale, next-generation sequencing collaborations, such as The Cancer Genome Atlas, have already identified drivers and vulnerabilities of urothelial carcinoma. This disease has a high degree of mutational heterogeneity and a high frequency of somatic mutations compared with other solid tumours, potentially resulting in an increased neoantigen burden. Mutational heterogeneity is mediated by multiple factors including the apolipoprotein B mRNA editing enzyme catalytic polypeptide family of enzymes, smoking exposure, viral integrations, and intragene and intergene fusion proteins. The mutational landscape of urothelial carcinoma, including specific mutations in pathways and driver genes, such as FGFR3, ERBB2, PIK3CA, TP53, and STAG2, affects tumour aggressiveness and response to therapy. The next generation of therapies for urothelial carcinoma will be based on patient-specific targetable mutations found in individual tumours. This personalized-medicine approach to urothelial carcinoma has already resulted in unique clinical trial design and has the potential to improve patient outcomes and survival.

UR - http://www.scopus.com/inward/record.url?scp=85011886935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011886935&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2017.11

DO - 10.1038/nrurol.2017.11

M3 - Review article

C2 - 28169993

AN - SCOPUS:85011886935

VL - 14

SP - 215

EP - 229

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 4

ER -